Patch

• US 4,685,911 A
• Filed: 02/08/1985
• Issued: 08/11/1987
• Est. Priority Date: 02/21/1984
• Status: Expired due to Term

• Current Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Astellas Pharma Incorporated)
• Original Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Astellas Pharma Incorporated)
• Inventors: Mitomi, Mitsuo, Konno, Yutaka, Aruga, Masayoshi, Sonobe, Takashi, Kawata, Hiroitsu
• Primary Examiner(s): Rosenbaum, C. Fred
• Assistant Examiner(s): Vinyard, Sherri E.
• Application Number:
  US06/699,585
• Time in Patent Office: 914 Days
• Field of Search: 604/288, 604/291, 604/364, 604/896, 604/897, 424/19, 424/28, 424/38
• US Class Current: 424/450
• CPC Class Codes: A61K 47/44 Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

A patch having good transdermal property which utilizes a suppository base e.g. triglyceride of a vegetable saturated fatty acid having 12 to 18 carbon atoms together with a penetration enhancer.

Claims

1. A transdermal patch comprising a solution or a suspension of a drug component wherein said drug component is selected from the group consisting of nicardipin hydrochloride, nifedipine, dipyridamole, formoterol fumarate, indenolol and γ

-oryzanol, and when nicardipine hydrochloride is in solution, it is dissolved in;

(i) a mixed solvent of an aqueous urea solution, lactic acid and propylene glycol, or

(ii) a mixed solvent of an aqueous urea solution, benzyl alcohol, and propylene glycol, and when dipyridamole is in solution, it is dissolved in a mixed solvent of an aqueous urea solution, lactic acid and propylene glycol, and wherein said drug component is uniformly dispersed in a base mainly comprising a triglyceride of a vegetable saturated fatty acid having 12 to 18 carbon atoms together with a penetration enhancer; and

wherein a heating element is disposed at the side of the patch opposite to the side thereof to be applied to the skin.

2. The transdermal patch of claim 1, wherein said heating element is comprised of iron powder and generates heat in the presence of oxygen and water.

3. The transdermal patch of claim 1, wherein the heating element is comprised of iron powder and activated carbon.